Cargando…
Overcoming MCL-1-driven adaptive resistance to targeted therapies
Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clini...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985132/ https://www.ncbi.nlm.nih.gov/pubmed/31988312 http://dx.doi.org/10.1038/s41467-020-14392-z |